Leading global law firm, Baker McKenzie, has advised CSL Limited in all legal matters on its partnership with Thermo Fisher Scientific Inc. CSL (ASX:CSL), a leading global biotechnology company with a dynamic portfolio of life-saving medicines.
The strategic partnership was created to help meet the increasing demand for biologic therapies while also accelerating CSL’s broader manufacturing objectives. Through a long-term lease agreement with CSL, Thermo Fisher will operate a new state-of-the-art biologics manufacturing facility in Lengnau, Switzerland, when construction is completed in 2021. The site will feature highly flexible bioproduction technologies, including single-use and stainless steel, to provide a pathway from development to large-scale production as customers’ needs increase.
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding USD 25 billion. The organization's global team of more than 75,000 colleagues delivers a combination of innovative technologies, purchasing convenience and pharmaceutical services through their industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.
“Through this strategic partnership with Thermo Fisher, CSL will now be able to access a wide range of capabilities provided by a leading pharma services provider, and we are confident that the management of the Lengnau facility and team will be in the very best of hands,” said Paul McKenzie, Chief Operating Officer, CSL.
Baker McKenzie's Zurich based team that completed the transaction consisted of Dr. Alexander Wyss, Dr. Peter Reinert, Boris Wenger, Johanna Moesch, Michael Zeller, Julia Schieber and Roger Thomi.